Who to call at Kalaris Therapeutics, Inc., and when
Fundz watches for the moments Kalaris Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Kalaris Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kalaris Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kalaris Therapeutics, Inc.. With Fundz connected, it knows.
Kalaris Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.viracyte.com2 executive changes at Kalaris Therapeutics in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Kalaris Therapeutics appointed Matthew Gall as Chief Financial Officer, Treasurer, and principal financial officer, effective November 3, 2025. Gall previously served as CFO of iTeos Therapeutics, and the filing discloses no compensation terms.
Key Takeaways
Matthew Gall takes the CFO, Treasurer, and principal financial officer roles at Kalaris Therapeutics effective November 3, 2025.
Gall previously served as Chief Financial Officer of iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company.
2 more takeaways
Filing Overview
What This Means
Kalaris Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.